Emer Cooke, EMA executive director (Geert Vanden Wijngaert/AP Images)
July 27, 2022 01:45 PM EDTUpdated 06:47 PM
Coronavirus

EMA re­views re­pur­posed ex­per­i­men­tal can­cer drug for Covid-19, even with­out a sub­mis­sion

Zachary Brennan

Senior Editor

In a rare move for any reg­u­la­tor, the Eu­ro­pean Med­i­cines Agency said Wednes­day it’s be­gun re­view­ing da­ta on the use of an ex­per­i­men­tal can­cer drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times